Research programme: topoisomerase II inhibitors - Reata Pharmaceuticals

Drug Profile

Research programme: topoisomerase II inhibitors - Reata Pharmaceuticals

Alternative Names: Doxorubicin analogues - Reata; Reata 769; RTA 769; WP769

Latest Information Update: 12 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Reata Pharmaceuticals
  • Class
  • Mechanism of Action Apoptosis stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Cancer

Most Recent Events

  • 09 May 2007 Preclinical data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the pharmacokinetics section
  • 19 Apr 2006 This programme is still in active development
  • 31 Oct 2004 Preclinical trials in Brain cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top